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Abstract
Recent advances in the adoption and use of health information technology (HIT) have had a dramatic impact on
the practice of medicine. In many environments, this has led to the ability to achieve new efficiencies and levels
of safety. In others, the impact has been less positive, and is associated with both: 1) workflow and user experience
dissatisfaction; and 2) perceptions of missed opportunities relative to the use of computational tools to enable data-
driven and precise clinical decision making. Simultaneously, the “pipeline” through which new diagnostic tools and
therapeutic agents are being developed and brought to the point-of-care or population health is challenged in terms
of both cost and timeliness. Given the confluence of these trends, it can be argued that now is the time to consider
new ways in which HIT can be used to deliver health and wellness interventions comparable to traditional approaches
(e.g., drugs, devices, diagnostics, and behavioral modifications). Doing so could serve to fulfill the promise of what has
been recently promoted as “precision medicine” in a rapid and cost-effective manner. However, it will also require the
health and life sciences community to embrace new modes of using HIT, wherein the use of technology becomes a
primary intervention as opposed to enabler of more conventional approaches, a model that we refer to in this
commentary as “interventional informatics”. Such a paradigm requires attention to critical issues, including: 1)
the nature of the relationships between HIT vendors and healthcare innovators; 2) the formation and function
of multidisciplinary teams consisting of technologists, informaticians, and clinical or scientific subject matter
experts; and 3) the optimal design and execution of clinical studies that focus on HIT as the intervention of
interest. Ultimately, the goal of an “interventional informatics” approach can and should be to substantially
improve human health and wellness through the use of data-driven interventions at the point of care of broader
population levels. Achieving a vision of “interventional informatics” will requires us to re-think how we study HIT
tools in order to generate the necessary evidence-base that can support and justify their use as a primary means
of improving the human condition.
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Background
Much has been written in the contemporary scientific
literature and general media concerning the promise of
widespread adoption and use of Health Information
Technology (HIT). The reported benefits of HIT include
improved healthcare quality and safety, decreased costs,
and an enhanced ability to conduct research that can, in
turn, inform new approaches to healthcare delivery and
wellness promotion [1, 2]. More recently, the United
States government has announced a Precision Medicine
initiative, which includes as part of its objectives the
rapid translation of scientific knowledge generated via
research programs into actionable, evidence-driven in-
terventions aimed at improving the health of individuals
and populations [3, 4]. Taken as a whole, these efforts
represent an exciting inflection point in the history of
the health and life sciences. It is our perspective that the
power of data analytics can be harnessed in such a con-
text to fundamentally reshape the ways in which we care
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for patients, and perhaps more importantly, prevent dis-
ease in the first place.
In recent commentaries, we have described the need
for a healthcare system that enables not only evidence-
based medicine (EBM) but also evidence-generating
medicine (EGM), wherein the practice of medicine, sys-
tematic learning, and the promotion of health become
cyclical, synergistic and data-centric [5]. Even as such a
system relies upon robust information systems, concerns
have been raised about the capabilities and functionality
of current HIT platforms to meet such aspirational
goals. These critiques have included concerns about: 1)
the effective end-user adoption and utilization of clinical
decision support systems [6–9]; 2) challenging interfaces
and usability issues surrounding HIT platforms that may
have a negative impact on “real world” workflow and
productivity [2, 9, 10]; and 3) restrictive vendor behav-
iors that make it difficult to leverage HIT systems for the
purposes of integrating and interacting with diverse and
complex data types [11–13]. At a high level, these issues
speak to a confluence of multiple important areas that
impact the use and utility of HIT, including but not lim-
ited to healthcare delivery science, biomedical informat-
ics, human factors, cognitive science, and socio-cultural
engineering. While we will not be able to address each
of the aforementioned areas in a comprehensive manner,
we will attempt to address them in this commentary in a
broad manner by discussing the types of characteristics
that define the present healthcare data and information
technology “ecosystem”, specifically:
1) Rapid and broadening adoption of HIT platforms
provides a technological basis for improving our
healthcare delivery and research enterprises;
2) Such platforms will become even more important to
the delivery of care and the promotion of wellness as
we seek to adopt a Precision Medicine approach;
3) The healthcare and life science community are in
need of a well informed and supported evidence-
base that can support and enable the use of HIT as a
primary means of impacting individual patients and
their communities; and
4) Creating such an evidence-base will require the
study of HIT in a manner that allows for the focused
evaluation of data-driven interventions as a primary
end-point, while simultaneously seeking to under-
stand the complex technology, human, and environ-
mental issues that predispose or influence such
strategies.
It is this last characteristic of the HIT ecosystem that
is the our focus, namely the need for a new approach to
clinical research that enables the generation of the re-
quired evidence-base that will in turn allow us to more
effectively and comprehensively use HIT to impact indi-
vidual patients and their communities from a health and
wellness standpoint. We will refer to this type of ap-
proach as Interventional Informatics (I2), and define it
as follows:
Interventional Informatics (I2) an approach to using
HIT in a manner that improves clinical decision-
making, care delivery processes and/or population
health strategies while simultaneously enabling sys-
tematic evidence generation through routine practice.
Given such a working definition, it can be seen that
the primary objective of I2 is to enable quantifiable,
patient-centric improvements in health and wellness
through the use of precision, data-driven interventions.
In this way, I2 emphasizes an active and patient-centric
use of HIT that can impact health and wellness in a
measurable manner, analogous to more traditional ap-
proaches such as medications or clinical procedures.
This stands in contrast to traditional studies where Bio-
medical Informatics theories and methods are used to
inform, support, or facilitate the generation of new clin-
ical or population health evidence, but are not used as
the primary intervention strategy (e.g., where technology
and data support or enable a diagnostic or therapeutic
activity) . In this manner, it is the proximity to patients,
and the goal of directly impacting health outcomes that
delineates what is and is not I2.
Discussion
Introducing interventional informatics: a new approach to
studying primary hit interventions to improve human
health and wellness
As was noted previously, in most contemporary clinical
studies, the prevailing paradigm for the application of
informatics theories and methods follows a pattern such
that theories and methods are utilized to: 1) inform the
design of a study focusing on a traditional intervention
(e.g., a drug, device, or diagnostic method); 2) support
the collection and management of data generated during
the execution of that study; and 3) facilitate the analysis
of such data and determination of findings that serve to
advance the biomedical knowledge base [14]. The defin-
ing role of informatics in this traditional paradigm is
that of being a secondary substrate upon which primary
interventions are delivered, studied and empirically jus-
tified. In contrast, the I2 approach we have defined
herein promotes the use of informatics theories and
methods to: 1) design and implement the primary inter-
vention(s) to be studied; 2) drive the execution of such
intervention(s) via the delivery and instrumentation of
technology-based mechanisms to promote health or
manage the treatment of disease; and 3) contextualize
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and focus the analysis of ensuing results. These steps in
aggregate are intended to establish an evidence-base via
which informatics interventions become a primary
means of impacting patient health and wellness, rather
than serving in a facilitating role. The creation and
widespread use of such an evidence base has significant
benefits in scenarios amenable to technology-based in-
terventions, wherein the time, cost, and failure rate of
generating and applying effective clinical interventions
can be substantially reduced, while simultaneously im-
proving the return-on-investment and patient benefits
afforded by widespread HIT adoption. A comparison of
these two approaches as they relate to a high-level re-
search project design and ensuing evidence generation
is shown in Fig. 1.
Informatics as the intervention: rethinking the Clinical
Research Paradigm to develop an I2 evidence base
Implementing an I2 approach in order to generate the
requisite evidence for the use of HIT as a primary inter-
vention will require the extension and enhancement of
traditional clinical research frameworks that focus on
traditional therapeutic agents, devices, and diagnostic
methods, in order to fully account for the nature of
technology-based intervention strategies. A comparison
and discussion of potential points of contrast between
traditional and I2-centric approaches to clinical research
is provided below, and illustrated in Fig. 2. Of note in
regards to this figure is an approximate comparison of
the timelines and resources associated with traditional
clinical studies as contrasted with an I2-centric approach
wherein an intervention may be thought of as a data-
driven application or “app.” We believe that the magni-
tude of this comparison is valid, while simultaneously
acknowledging that due to the limited sources and biases
of the available knowledge base (e.g., having being gener-
ated via non-scholarly evaluations of the field) that
serves to define such information, such data points rep-
resent a rough approximation at best.
Phase 0: In a traditional clinical study, early stage re-
search (Phase 0 or pre-clinical phase) focuses on the effect
or measurement capabilities of the new therapy or diag-
nostic approach relative to the physiological phenomena
of interest. This stage tends to build on substantial prior
basic science research. Outcomes often involve the meas-
urement of direct or surrogate physiological processes or
products. In an I2 paradigm, the basic premise of this
phase would remain the same, with a potential refocusing
on broader systems-based phenomena as an alternative to
a pathophysiologic state. For example, such a systems-
level approach could involve the interplay of patients,
providers, and Electronic Health Records (EHRs) as
they are combined to enable the tailored delivery of in-
formation and its impact on modifiable risk factors for
a given disease state. Outcomes could include end-user
acceptance and/or usability of the intervention as a
surrogate for the ability of stakeholders to adopt and ef-
fectively use the new technology.
Phase I: In a traditional clinical study, the research
questions addressed in a Phase I study usually focus on
the safety of the new therapy or diagnostic approach. In
an I2 paradigm, safety would still remain a focus, as
would scalability of the technology, which could dir-
ectly impact safety in later study phases. For example, if
a technology-based intervention that uses a complex
algorithm is computationally tractable in small scale
studies (being computable in a sufficiently short time
frame so as to be usable at the point-of-care), but can-
not be reasonably calculated for larger numbers of pa-
tients in real-time, then substantial safety concerns
would be raised in terms of delivering said intervention
for use in general clinical practice. This is the type of
question that can and should be addressed in Phase I of
an I2 paradigm study.
Fig. 1 Overview of the transition required from a traditional role for informatics in healthcare research and innovation to one that is interventional in
nature. The core of this model is the rethinking of the type of evidence to be generated, and the corresponding focus of studies contributing to such
a knowledge base. In this figure, we compare and contrast the way in which informatics theories and methods apply to the design, execution, and
analysis of a given area of inquiry, shifting from a support or enabling role to one that is the direct and primary focus of ensuing research programs
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Phase II: When conducting a traditional clinical study,
Phase II research is often concerned with the effective-
ness of the diagnostic or therapeutic approach being
studied. Such efficacy is normally measured by using
one or more markers for the presence of disease or
response to therapy (e.g., bio-markers). In a similar man-
ner, the I2 paradigm can be used to study efficacy of a
technology-based intervention. Such efficacy can be
measured via a data-driven marker, such as those associ-
ated with measurable clinical phenotype characteristics
or patient reported outcomes. As a result, the goal of
this phase is to identify whether the technology inter-
vention is having an impact or effect on the desired
physiological, behavioral, or other end-point targeted by
the I2 approach.
Phase III: The I2 paradigm diverges more substantially
from traditional Phase III research designs. In a norma-
tive clinical trial, Phase III research would extend Phase
II to compare outcomes or indicators of efficacy with a
gold standard, such as a prevailing treatment or diagnos-
tic modality. In this scenario, a pair-wise comparison is
used to examine two comparable approaches that address
a common driving clinical problem. In contrast, the Phase
III of the I2 approach compares the performance of a
technology-based intervention with a conventional tech-
nique (such as a drug or qualitative judgment conducted
by a physician). Such a comparison of the relative benefits
of the informatics-based and non-informatics based ap-
proaches satisfies what is commonly known as a compara-
tive effectiveness research question, which traditionally
involves assessments of comparative benefits in areas such
as clinical outcome, cost, and quality.
Phase IV: Finally, in both a traditional clinical study as
well as in the I2 paradigm, Phase IV or “post-market” re-
search involves the long term and longitudinal monitor-
ing of the effects of a diagnostic or therapeutic approach
as observed in an a population situated in normative set-
tings (e.g., as part of routine care or health promotion
activities), as opposed to a research context.
An example of the I2 paradigm: the SPHERE project
As was noted previously, EHR platforms hold great
promise relative to the ability to improve patient care
and outcomes, especially when incumbent clinical deci-
sion support (CDS) functionality is used to address
modifiable and measurable risk factors for disease onset
or progression. A primary example of a driving clinical
problem in which these types of factors are of great im-
portance is the management of cardiovascular disease
(CVD) risk. EHR-based interventions in this realm
have a strong evidence base in CVD prevention and
the potential to improve clinical decision-making and
healthcare delivery while maintaining an efficient
healthcare encounter workflow. To this end, interven-
tional informatics technology with a flexible, robust
architecture can be used to deliver precision medicine
on a large scale.
However, and as was introduced previously, there
are a variety of barriers to the efficient use of clinical
data collected via an EHR at the point-of-care so as
Fig. 2 Overview of the “Interventional Informatics” paradigm, aligned with traditional clinical study phases and outcomes. These overall approaches
are also contrasted relative to their average cost and timeliness. In this figure, we show how traditional types of research questions commonly pursued
in a clinical trial or study can be modified and applied to enable the study of interventions that are primarily data-driven and technology focused
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to support risk identification and management. For
example, relevant vital signs, laboratory results, medi-
cation usage, and health behavior indicators are often
captured in multiple structured, semi-structured, and
unstructured formats that are distributed throughout
a variety of screens and interfaces in most commonly
used EHR platforms. Further, even if such data are iden-
tified and used for a CDS alerting strategy, the ways in
which ensuing alerts can be programmed and delivered to
the end-user are usually relatively simplistic (involving
basic logical operations applied to structured data ele-
ments and the presentation of the alert using textual user
interface elements). These types of challenges are repre-
sentative of an even broader spectrum of potential barriers
to the satisfaction of clinical and patient information
needs, human-computer interaction optimization, and
workflow integration, not to mention missed opportun-
ities to engage patients in meaningful dialogues relative to
clinical decision-making and health promotion.
In response to these types of challenges and opportun-
ities, and motivated by the clinical importance of CVD risk
management, we developed and studied an EHR-integrated
tool whereby CVD data are integrated, analyzed, and
presented using state-of-the-art visualization methods [15].
This technology, known as the Stroke Prevention in
Healthcare Delivery Environments (SPHERE) tool, was
explicitly designed from the outset with an interactive inter-
face to enhance patient-provider communication around
CVD relevant behavioral risk factors, thus providing a data-
driven health and wellness intervention via which those risk
factors would ideally be discussed and managed by patients,
and their caregivers and healthcare providers at the point-
of-care and beyond. In order to study the efficacy and im-
pact of this patient-centric intervention, we conducted a
practice-randomized study of the SPHERE tool in primary
care settings. In this study design, a traditional case and
control group comparison approach was employed, and the
tool was assigned to comparable clinical practice settings
(where the unit of randomization was the practice itself).
At the conclusion of the study, we were able to identify
significant and positive changes in both Body Mass Index
(BMI) and Hemoglobin A1C measurements for the popula-
tion of patients in the clinic that received the SPHERE
intervention when compared to the control clinic. Both of
these measures related to important and modifiable risk
factors for CVD onset, and as such, are viable surrogates
for showing the clinical efficacy of the intervention strategy.
Full details concerning this study, its design, and results can
be found in a number of publications [16, 17]. Furthermore,
at a high level, this study is a primary example of the previ-
ously introduced I2 paradigm, whereby:
1) The design and implementation of the primary
intervention underlying our study was data-centric in
nature and focused upon an informatics based
approach to improving population health, in this
case as it relates to CVD risk;
2) The execution of our intervention focused on the
delivery and instrumentation of a technology-based
mechanism that leveraged extant HIT platforms,
and further, our informatics-based approach to man-
aging disease-specific risk factors was intended to
have a direct and measurable impact on a driving
clinical problem;
3) The focus of our analysis of the study was on the
efficacy and impact of said technology-based
mechanism, and employed a well-validated clin-
ical research model to generate high quality clin-
ical evidence.
Challenges and opportunities surrounding interventional
informatics (I2) research and innovation
As was introduced above, substantial opportunity exists
to advance the speed and cost-effectiveness of evidence
generation in support of healthcare delivery via the
rigorous study of interventions that are primarily tech-
nology based. However, there remain challenges to real-
izing such a vision, including:
 One of the primary platforms for designing and
implementing technology interventions for the
clinical environment is the implementation of novel
functionality within EHR systems. However, due to
technical constraints, variable data and
programmatic standards compliance, and restrictive
licensing and usage policies, the ability to implement
such interventions is both complicated and yields
inconsistent generalizable success across
environments and platforms. This challenge of
vendor propriety, and the need to introduce
technical and regulatory frameworks that overcome
said barriers, have been explained in detail in recent
publications [8, 11, 12]. Such measures can and
should be one of the top priorities for the healthcare
research and delivery communities if we are going
to realize the full value of our collective technology
investments to-date.
 The design and conduct of I2 paradigm studies will
necessitate the participation of multi-disciplinary
teams of investigators and clinicians, working to-
gether, and motivated by common benefits and in-
centive structures. However, despite over a decade
of community dialogue concerning the importance
of supporting and enabling team science, major cul-
tural, workflow, resource and policy barriers impede
such team formation and operation. As such, realiz-
ing the full benefits of the I2 paradigm will require a
redoubling of efforts to address such gaps and create
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new modes of team formation, support and incen-
tive structures. This will also by necessity require a
full consideration of critical environmental, funding,
and policy issues that impact such collaborative ef-
forts. A glimpse of how to address these types of
challenges is provided in a recent publication by one
of the authors (PJE) concerned with the need for a
financial model that encourages and enables partici-
pation in research by front-line clinicians [18].
 Finally, while we have presented an overarching
model for the types of inquiries to be asked and
answered during the different stages of an archetypal
I2 research program, there remains much work to be
done to more fully formalize study designs and best
practices that can express the range of hypotheses
and research questions incumbent to this emergent
model. Examples of issues here include the
identification of metrics and end-points to be mea-
sured, mechanisms of managing bias (both implicit
and explicit), and satisfaction of sampling and repro-
ducibility concerns through appropriate modeling
and qualification of results [14].
The work required for the preceding mitigating ap-
proaches can and should be motivated by the funda-
mental differentiation of potential costs and benefits
associated with traditional clinical studies that may take
upwards of 20 years and cost up to 5B USD, when com-
pared to I2 paradigm studies, that can be completed in
as little as 6 months with a cost around 250,000 USD
based upon current survey data from the Kinvey group
[10]. Furthermore, we believe that the rapidly maturing
fields of study surrounding the component approaches
that make up an I2 paradigm are well positioned to ad-
dress many if not all of the preceding challenges in a
timely and compelling manner, given sufficient support
and attention by the research and clinical practice com-
munities in equal measure.
Conclusions
Advances in the adoption and use of HIT have and con-
tinue to make a dramatic impact on the practice of
medicine. Building upon this, and in an effort to achieve
an EGM paradigm [5], it can be argued that now is the
time to pursue new means of studying HIT as the inter-
ventional strategy that is needed in order to realize the
promise of precision medicine. Achieving this goal will
ultimately require the health and life sciences communi-
ties to embrace a new mode of using and studying HIT,
which we have introduced here as “interventional inform-
atics” or I2. Achieving this vision will require our commu-
nity to address critical issues, including the: 1) nature of
the relationships between HIT vendors and healthcare in-
novators; 2) formation and function of multidisciplinary
teams consisting of technologists and clinical or scientific
subject matter experts; and 3) optimal design and execu-
tion of clinical studies that focus on HIT as the interven-
tion of interest, including a thorough understanding of the
resource and financial needs underlying such investiga-
tions. Furthermore, addressing these types of open ques-
tions will also require thoughtful consideration of how the
“interventional informatics” or I2 paradigm is best posi-
tioned in the taxonomic definitions that serve to organize
the broader field of Biomedical Informatics, and in par-
ticular, whether such an approach to research constitutes
a new sub-discipline of the field, an extension to an exist-
ing sub-discipline such as Clinical Research Informatics
(CRI), or a cross-cutting experimental framework. While a
full treatment of all of the preceding challenges and
opportunities is beyond the scope of a single commentary
such as this, it is our hope that by raising the fundamental
questions required to implement and pursue studies
aligned with an I2 paradigm, we can catalyze the necessary
community dialogue and ensuing efforts to overcome
such barriers. Ultimately, while there exist substantial
challenges to achieving an I2 paradigm, a concerted and
focused effort to address these issues has the potential to
yield substantive and highly impactful changes in the
healthcare system by which technology assumes a primary
role in delivering high quality, safe, and cost effective clin-
ical care and wellness promotion, and is thus worthy of
further pursuit, energy, and effort.
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